ArticleFrontiers in microbiology2016
Biosynthesis, Chemical Structure, and Structure-Activity Relationship of Orfamide Lipopeptides Produced by Pseudomonas protegens and Related Species.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 96 citations in OpenAlex.
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 24: Suitability of taxonomic units notified to EFSA until March 2026.EFSA journal. European Food Safety Authority · 2026Article
- Regulation of cyclic lipopeptide orfamide A biosynthesis in Pseudomonas protegens by the Gac-Rsm-LuxR Cascade.Nucleic acids research · 2026Article
- Microgravity effects on secondary metabolism of plant-affecting bacteria.Microbiology spectrum · 2026Article
- Paenidepsins are a Family of Lipopeptides fromJournal of natural products · 2026Article
- Higher-Level Structural Classification of Pseudomonas Cyclic Lipopeptides through Their Bioactive Conformation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Predicting bacterial-mediated entomopathogenicity through comparative genomics and statistical modeling.Microbiology spectrum · 2026Article
- Pseudomonas protegens as a biocontrol agent against phytopathogenic fungi - mini review.World journal of microbiology & biotechnology · 2025Review
- Genetic Drivers of Plant Root Colonisation by the Biocontrol Agent Pseudomonas protegens Pf-5.Environmental microbiology reports · 2025Article
- Complete Genome Analysis and Antimicrobial Mechanism ofMicroorganisms · 2025Article
- Effect ofLife (Basel, Switzerland) · 2025Article
- Natural Cyclic Peptides: Synthetic Strategies and Biomedical Applications.Biomedicines · 2025Review
- Pyoluteorin-deficient Pseudomonas protegens improves cooperation with Bacillus velezensis, biofilm formation, co-colonizing, and reshapes rhizosphere microbiome.NPJ biofilms and microbiomes · 2024Article
- Genomic Insights intoInternational journal of molecular sciences · 2024Article
- Review
- Resistance towards and biotransformation of a Pseudomonas-produced secondary metabolite during community invasion.The ISME journal · 2024Article
- Does regulation hold the key to optimizing lipopeptide production inFrontiers in bioengineering and biotechnology · 2024Review
- Stereomeric Lipopeptides from a Single Non-Ribosomal Peptide Synthetase as an Additional Source of Structural and Functional Diversification inInternational journal of molecular sciences · 2023Article
- Relation of pest insect-killing and soilborne pathogen-inhibition abilities to species diversification in environmental Pseudomonas protegens.The ISME journal · 2023Article
- Charting the Lipopeptidome of Nonpathogenic Pseudomonas.mSystems · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orfamide-type cyclic lipopeptides (CLPs) are biosurfactants produced by Pseudomonas and involved in lysis of oomycete zoospores, biocontrol of Rhizoctonia and insecticidal activity against aphids. In this study, we compared the biosynthesis, structural diversity, in vitro and in planta activities of orfamides produced by rhizosphere-derived Pseudomonas protegens and related Pseudomonas species. Genetic characterization together with chemical identification revealed that the main orfamide compound produced by the P. protegens group is orfamide A, while the related strains Pseudomonas sp. CMR5c and CMR12a produce orfamide B. Comparison of orfamide fingerprints led to the discovery of two new orfamide homologs (orfamide F and orfamide G) in Pseudomonas sp. CMR5c. The structures of these two CLPs were determined by nuclear magnetic resonance (NMR) and mass spectrometry (MS) analysis. Mutagenesis and complementation showed that orfamides determine the swarming motility of parental Pseudomonas sp. strain CMR5c and their production was regulated by luxR type regulators. Orfamide A and orfamide B differ only in the identity of a single amino acid, while orfamide B and orfamide G share the same amino acid sequence but differ in length of the fatty acid part. The biological activities of orfamide A, orfamide B, and orfamide G were compared in further bioassays. The three compounds were equally active against Magnaporthe oryzae on rice, against Rhizoctonia solani AG 4-HGI in in vitro assays, and caused zoospore lysis of Phytophthora and Pythium. Furthermore, we could show that orfamides decrease blast severity in rice plants by blocking appressorium formation in M. oryzae. Taken all together, our study shows that orfamides produced by P. protegens and related species have potential in biological control of a broad spectrum of fungal plant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.